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Abstract
Background: PCA3 has been included in a nomogram outperforming previous clinical models for the prediction of
any prostate cancer (PCa) and high grade PCa (HGPCa) at the initial prostate biopsy (IBx). Our objective is to
validate such IBx-specific PCA3-based nomogram. We also aim to optimize the use of this nomogram in clinical
practice through the definition of risk groups.
Methods: Independent external validation. Clinical and biopsy data from a contemporary cohort of 401 men with
the same inclusion criteria to those used to build up the reference’s nomogram in IBx. The predictive value of the
nomogram was assessed by means of calibration curves and discrimination ability through the area under the
curve (AUC). Clinical utility of the nomogram was analyzed by choosing thresholds points that minimize the
overlapping between probability density functions (PDF) in PCa and no PCa and HGPCa and no HGPCa groups, and
net benefit was assessed by decision curves.
Results: We detect 28 % of PCa and 11 % of HGPCa in IBx, contrasting to the 46 and 20 % at the reference series.
Due to this, there is an overestimation of the nomogram probabilities shown in the calibration curve for PCa. The
AUC values are 0.736 for PCa (C.I.95 %:0.68–0.79) and 0.786 for HGPCa (C.I.95 %:0.71–0.87) showing an adequate
discrimination ability. PDF show differences in the distributions of nomogram probabilities in PCa and not PCa
patient groups. A minimization of the overlapping between these curves confirms the threshold probability of
harboring PCa >30 % proposed by Hansen is useful to indicate a IBx, but a cut-off > 40 % could be better in series
of opportunistic screening like ours. Similar results appear in HGPCa analysis. The decision curve also shows a net
benefit of 6.31 % for the threshold probability of 40 %.
Conclusions: PCA3 is an useful tool to select patients for IBx. Patients with a calculated probability of having PCa
over 40 % should be counseled to undergo an IBx if opportunistic screening is required.
Background
Urologists need tools to optimize the performance of an
initial prostate biopsy (IBx) as this procedure is related
to emotional stress derived from a potential cancer diag-
noses [1] and adverse biopsy-related events such as
bleeding, urinary obstructions and infections [2, 3].
PCA3 as a single biomarker has been approved by
the FDA to guide prostatic biopsy (Bx) in men with a
negative previous IBx. On the other hand, we and
others [4–7] have reported better results on patients
not previously biopsied.
Nomograms help clinicians to estimate the probabil-
ities associated in different scenarios of the disease and
are essential for counseling patients [8–11]. PCA3 has
been included in nomograms to predict prostate cancer
(PCa) at IBx or repeated Bx [5, 12–14]. In this paper we
focus our attention into a recently published nomogram
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by Hansen et al. that also studied PCA3 as a marker for
the prediction of any PCa at the IBx and its ability to
identify high-grade PCa (HG-PCa; considered as Gleason
score at biopsy ≥ 7). These authors concluded that the
addition of PCA3 to a set of standard risk factors improves
significantly the discrimination ability of a predictive model
of PCa, avoiding unnecessary IBx [15].
Our aim is to externally validate such IBx-specific
PCA3-based nomogram in a single center cohort and to
optimize its use in clinical practice through the defin-
ition of risk groups. We used a graphical procedure to
establish a threshold point for this nomogram through
the use of probability density functions (PDF) of harbor-
ing or not PCa, favoring its implementation for clinical
use [16].
Methods
Patient population
We enrolled 613 men scheduled for IBx with PCA3
testing in our daily practice. Selection criteria were
the same as in the Hansen’s cohort [15] that was
built with 692 patients from two prospective multi-
institutional studies in Europe [4] and USA [17] with
suspicious DRE or PSA between 2.5 and 10 ng/ml
and a minimum of 10 cores IBx. In case of suspicious
DRE, men with PSA between 10 and 20 ng/ml were
included. Prostate volume was determined by ultra-
sound and urine infection ruled out. Finally, from the
whole series 401 men referred to IBx met all the
established selection criteria. This study was approved
by the Ethics Committee of the Fundación Instituto
Valenciano de Oncología (ref. number. 2010–20). At
the moment of the urine collection for the PCA3
analysis all patients gave their consent for the use of
the leftover urine and associated information for research
purposes following the standards set by the Institutional Bio-
bank (Spanish Biobank Registry number: B.0000773; https://
biobancos.isciii.es/ListadoBiobancos.aspx?id=B.0000773).
Clinical evaluation
PCA3 was performed following manufacturer’s instruc-
tions [18] and DRE was reported as unsuspicious versus
suspicious. Transrectal ultrasound (TRUS)-derived total
prostate volume was calculated using the prostate ellipse
formula (0.52 × length × width × height). 10–12 core sys-
tematic laterally directed TRUS guided biopsies were
performed. All biopsy specimens were evaluated by a
single experienced uropathologist (AC).
Statistical analysis
The external validation was performed analyzing the
calibration, discrimination and clinical utility [10, 19].
The calibration is analyzed by means of calibration
curves and the two informative parameters: Intercept
(calibration-in-the-large) and Slope, which evaluate the
correspondence between the predicted and the actual
probabilities. To study the discrimination ability and the
clinical utility of the model, the empirical distributions
of probabilities of PCa in the PCa/No-PCa and HGPCa/
No-HGPCa populations have been estimated. Those
probabilities are estimated in the IVO cohort using the
Hansen nomogram by kernel density estimation [20].
The way in which the probability distributions of PCa pop-
ulations overlap is important to know how the model
discriminates between groups and to show the best thresh-
old to define risk groups for clinical use. Moreover, discrim-
ination has been quantified through the Receiver Operating
Characteristics (ROC) curve [21], the area under the ROC
curve (AUC) and its 95 % confidence interval (CI). We also
evaluate its clinical utility through Vickers’ decision curves
[22] that analyze the net benefit for different threshold
probabilities. Statistical analyses were performed using R
programming language v.3.1.0 [23].
Results
Table 1 summarizes the characteristics of patients of the
two multi-institutional studies included in the Hansen
study and the IVO cohort. Our PCa detection rates were
28 % (11 % HGPCa), clearly lower than the Hansen’s
series values of 46 % (20 % HGPCa). The median age
was 2 years lower in the IVO cohort, but interquartile
ranges (IQR) were very similar. Prostate volume results
were quite similar for the both cohorts, but importantly
the Wilcoxon signed rank test p-value <0.001 confirmed
differences with regard median PSA levels (5.2-Hansen
vs 4.3-IVO ng/ml). Also, differences were observed in
the percentage of patients with suspicious DRE (28.5 vs
10.7; p < 0.001) and with suspicious DRE and PSA be-
tween 10 and 20 ng/ml (4 vs 1 %; p < 0.01).
Median PCA3 values were 27 and 36 for Hansen and
IVO series respectively. The Wilcoxon signed rank test
showed that PCA3 median value in the IVO cohort (p <
0.001) showed a statistically significant difference with
the Hansen median value. Attending to the manufac-
turer threshold of 35, we observed 50.4 % of the IVO
series with PCA3 values above 35 and just 40.5 % for the
reference series. The test for equality of proportions had a
p-value < 0.001, therefore showing again statistically signifi-
cant differences between these cohorts. We observed de-
creasing sensibilities from lower to higher PCA3 cut-offs
for PCa detection in similar percentages of both series,
showing statistically significant differences in all thresholds
when compared to negative IBx.
Furthermore, Table 2 shows the univariant association
and the discrimination power measured by the AUC for
each predictor variable in the diagnosis of PCa and
HGPCa. Continuous PCA3 variable has the maximum
AUC value of 0.701 for PCa diagnosis in our series.
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Table 2 Univariant analyses and AUC for each variable for the detection of any PCa and HGPCa in Hansen’s series (black) and IVO
series (red)
Table 1 Data from men included in the referenced nomogram (in black) and from the IVO series (in red)
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Using the De Long test for comparison of AUC between
PCA3 and the rest of predictors, statistically significant
differences were established in all cases except for the
comparison with the prostatic volume.
In Fig. 1 we show the calibration curve. There is an
important overestimation in all range of probabilities for
the detection of any PCa, due to the difference in the
prevalence of PCa between the Hansen and the IVO
cohorts. The intercept and Slope values of −0.762 and
0.797 confirm a poor calibration.
Regarding the discrimination ability of the nomogram,
we obtained an AUC for the detection of any PCa of
0.736 (CI 95 %: 0.680–0.793) and a value of 0.786 (CI
95 %: 0.705–0.867) for the detection of HGPCa (Fig. 2).
The distribution of probabilities of PCa assigned by the
nomogram to our patients with and without real PCa
are shown in Fig. 3a, and for HGPCa/Non HGPCa in
Fig. 3b. These density functions curves show than 40 %
is the best cut off better pointing to the probability of
harboring any PCa above it (Fig. 3a), same value when
focusing on HGPCa (Fig. 3b).
Therefore, facing the decision of indicating an IBx, we
propose 40 % as a better cut off than the 30 % Hansen
et al. proposed for their nomogram. A higher number of
patients without PCa and particularly without HGPCa
are correctly classified under the threshold point of 40 %
of the nomogram, with a very scarce number of patients
with PCa and HGPCa missed in the interval between 30
and 40 % (Fig. 3a and b).
Finally, Vickers’ decision curves show the net benefit
obtained from the application of the Hansen’s nomo-
gram to the entire IVO-cohort. We check the improve-
ment provided by the model for different cut-off
probabilities (Fig. 4).
Discussion
Several nomograms optimize the indication of IBx, with
predictive accuracy estimates between 67 and 77 % [3,
24–26]. In particular, the PCA3-based nomogram vali-
dated here showed that the accuracy of the clinical
model was increased by 4.5–7.1 % related to PCA3 in-
clusion [15]. In this model, continuously coded PCA3
represented the most informative parameter in the predic-
tion of any PCa (AUC= 0.739) and HGPCa (AUC= 0.729).
In our univariate analyses, we also showed that continu-
ous coded PCA3 was the best predictive variable for the
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detection of any PCa (AUC= 0.701) and prostate volume
was slightly better to detect HGPCa (AUC= 0.723) than
continued coded PCA3 (AUC= 0.685). Checking different
cut-offs, 24 and not 21, showed the highest AUC for both
any PCa and HGPCa (Table 2). These findings agree with
previous studies [27]. We also tested categorized PCA3,
and we agree with the Hansen et al. series that continuous
coded PCA3 was the most informative variable to predict
PCa and HGPCa, therefore it should be considered this
way when building a nomogram. The non-linear effects of
PCA3 can be appropriately modeled using its continuous
form, thus adding more predictive power [28].
The calibration plot and the values of intercept and
slope showed a poor agreement between actual and
predicted probabilities obtained from the application of
the nomogram to our 401 men as a validation cohort
(Fig. 1). This fact is explained by the clear differences in
detection rates between both series. Our PCa detection
rate was 28 % (11 % HGPCa), closer to the expected
prevalence of PCa in contemporary series of opportunis-
tic screening, and the same features were 46 % (20 %
HGPCa) in the referenced series. The initial cohorts
which generated Hansen’s nomogram consisted in 570
patients enrolled from 4 North American sites with a
detection rate of PCa of 36 % (15 % HGPCa) [17] and
516 patients from a European multicenter study with a
detection rate of PCa of 40 % (19 % HGPCa) [4], closer
to our data. From the entire cohort of 1086 patients, 692
patients were finally considered to generate Hansen’s
nomogram and the proportion of PCa and HGPCa
increased substantially (46 % PCa and 20 % HGPCa)
from original cohorts. We think this fact could explain
their high prevalence of PCa and HGPCa, which over-
comes expected rates of PCa and HGPCa for patients
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with PSA between 2,5 and 10 ng/mL. In this sense we
think our detection rates are more similar to the reported
in the literature, with most men coming from opportunis-
tic screening scenarios. Only series with so extremely high
rate of PCa/HGPCa could expect a nice calibration plot.
In any case, a good calibration would had shown a good
performance of the Hansen et al. model in our series, but
a bad calibration doesn’t mean that the validated nomo-
gram is a bad predictive model in our series, but just a
different threshold point must be investigated.
We obtained slightly inferior AUC (0.736, CI95 %:0.680–
0.793) for any PCa detection that the referenced nomogram
(AUC 0.807, CI95 %:0.768–0.828), showing statistically
significant differences between AUCs (p-value = 0.02), but
similar to the other published external validation (0.764,
CI95 %:0.726–0.802) [27], p-value = 0.43, so we think the
model offers good discrimination ability. When we built a
logistic regression model using the same predictive vari-
ables and using PCA3 as a continuous value we obtain an
AUC of 0.769 (data not shown), very similar to the applica-
tion of Hansen nomogram in our series (Table 3). Recently,
a similar evaluation of the use of PCA3 as a continuous
predictor in a multivariate logistic regression model devel-
oped over 3073 patients from screening population in USA,
showed an AUC of 0.75 and 0.81 respectively for the
prediction of PCa and HGPCa respectively at the IBx [29].
In the decision curve analysis we obtained at a 30 %
threshold probability a net benefit 8.41 %, superior to
the baseline model, but far away of the >18 % recognized
for the model in the original series. For a threshold
probability of 40 % the net benefit obtained is 6.31 %.
Other authors have also shown that decision curve ana-
lysis confirmed a higher benefit when adding the PCA3
score (either continuous or binary with a cutoff of 35) to
the baseline model [27] in IBx. In the logistic regression
model built with our database using the continuous
PCA3 score, the net benefit is 6.90 % for the 40 %
threshold point, very similar to the Hansen nomogram
application.
Multivariate models translate multiple effects in one
number, which is the interpretation of the risk of harbor-
ing an event from 0 to 100 %. But we as clinicians take
decisions based on a reference value (PSA > 4 ng/ml,
free-PSA ratio < 15 %, etc.), counseling patients taking
based on them. With the aim of helping the clinician to
indicate or not an IBx, we investigated the probabilities
of the model to detect PCa through PDF [16]. These
density functions help us to choose thresholds to differ-
entiate groups of high and low risk probabilities of
harboring PCa (Fig. 3a) or HGPCa (Fig. 3b). The density
curves of probabilities are built from the probabilities of
having PCa assigned by the nomogram to each man. In
their X-axis, we reflect the range of possible probabilities
(0–100) of harboring PCa according to the nomogram.
In the Y-axis we range the density of patients from their
assigned probability of harboring PCa or HGPCa. We
can see the higher peak of density in PCa patients near
the X = 70 % probability of harboring PCa in Fig. 3a and
in HGPCa patients near 80 % in Fig. 3b. On the other
hand, this peak appears around X = 15–20 % for non
PCa/non HGPCa patients.
We can easily see how our PDF curves show a “valley”
between the “peak” of patients with PCa/HGPCa in the
range of high probabilities of harboring PCa (in the right
side of the graphic), and the “peak” of patients without
Table 4 Potential avoided initial biopsies (IBx), PCa and HGPCa detection and missed rates at IBx using different threshold
probabilities values
Threshold Biopsies Biopsies PCa detected PCa delayed HGPCa detected HGPCa delayed
Probability Perforrmed, n (%) Avoided, n (%) n (%) Diagnosis, n (%) n (%) Diagnosis, n (%)
>10 % 362 (90.3 %) 39 (9.7 %) 108 (97.3 %) 3 ( 2.7 %) 43 (97.7 %) 1 ( 2.3 %)
>20 % 295 (73.6 %) 106 (26.4 %) 99 (89.2 %) 12 (10.8 %) 40 (90.9 %) 4 ( 9.1 %)
>30 % 250 (62.3 %) 151 (37.3 %) 90 (81.1 %) 21 (19.9 %) 38 (86.4 %) 6 (13.4 %)
>35 % 228 (56.9 %) 173 (43.1 %) 88 (79.3 %) 23 (20.7 %) 37 (84.1 %) 7 (15.9 %)
>40 % 204 (50.9 %) 197 (49.1 %) 84 (75.7 %) 27 (24.3 %) 37 (84.1 %) 7 (15.9 %)
>45 % 187 (46.6 %) 214 (53.4 %) 80 (72.1 %) 31 (27.9 %) 36 (81.8 %) 8 (18.2 %)
>50 % 160 (39.9 %) 241 (60.1 %) 71 (64.0 %) 40 (36.0 %) 34 (77.3 %) 10 (22.7 %)
>60 % 98 (24.4 %) 303 (75.6 %) 55 (49.5 %) 56 (50.5 %) 28 (63.6 %) 16 (36.4 %)
Table 3 Logistic regression model using the same predictive
variables and using PCA3 as a continuous value
Clinical variables + PCA3 Clinical variables
Predictor variable O.R. (95 % C.I.) p-value O.R. (95 % C.I.) p-value
PSA 1.63 (1.21–2.20) 0,001 1.69 (1.27–2.26) <,001
Prostatic volume 0.54 (0.38–0.77) <,001 0.45 (0.32–0.63) <,001
DRE 3.57 (1.67–7.61) 0,001 3.64 (1.76–7.53) <,001
PCA3 3.19 (2.08–4.88) <,001
AUC 0.769 (0.72–0.82) 0.712 (0.66–0.77)
AUC comparison p-value = 0.008
Rubio-Briones et al. BMC Cancer  (2015) 15:633 Page 6 of 8
PCa/HGPCa in the range of low probabilities (in the left
side). This valley drives us to choose the threshold of
probability to classify patients in high or low risk of har-
boring PCa. A threshold point of 40 % instead of 30 %,
as proposed by Hansen et al., could be the best option
to translate the implementation of this nomogram in
our daily practice.
Applying the nomogram with a threshold of 40 % to
our 401 men, we would had saved 197 IBx (49.1 %), at a
cost of missing 27 any PCa (24.3 %) and 7 HGPCa
(15.9 %) (Table 4). For the threshold value of 30 %
provided by Hansen et al., we would had saved 151 IBx
(37.3 %) at a cost of missing 21 any PCa (19.9 %), and 6
HGPCa (13.4 %). Therefore, selecting 40 %, nor 30 %,
we would had saved 11.8 % IBx more just missing one
HGPCa more. This features would always improve the
results of taking single PCA3 cut offs values as a single
tool to decide IBx (Table 5), where we can check that if
we had chosen PCA3 > 21 we would had missed 15.9 %
HGPCa, similar to the 13 % observed by other authors
at IBx with a cut-off of 20 [30], but doing 12.2 % more
IBx that if we had applied the nomogram. We notice
that our small number of HGPCa (44 cases) could affect
our data on this population, as using the threshold point
of 40 % the percentage of missed HGPCa cases is
15.9 %, but the 95 % CI is 7.1–30.7 %.
It would had been desirable to compare the initial clin-
ical nomogram built without PCA3 evaluated by Hansen
et al. to ours, in order to know the clinical benefit of de-
termining PCA3, but that nomogram was not published.
We show in Table 3 that there are statistically significant
differences (p < 0.01) between models build with or with-
out PCA3 as predictor variable.
From a practical point of view, and in order to save
costs, we ask for PCA3 just in doubtful cases, in the way
Abern and Freedland propose [31]. If we had applied
the nomogram to our series, we would had obtained a
score of 121 total points (equivalents to a probability
of ≥ 40 %) in 204 men. Twenty-six of them would had
had 121 points without the need to test PCA3, so we would
had indicated the IBx saving costs. In the lower scenario,
178 would not had reached to 121 points adding the add-
itional 26 points dependent on a PCA3 > 21, but we think
that not using the aid of PCA3 at this scenario, knowing
the strength of PCA3 as a continuous variable and that
prostate volume could be undermeasured by hypogastric
sonography, that the cost of PCA3 would be worth while
for a better counseling of IBx to a men in this grey area.
Finally, this external validation in a single center over
a series of 401 patients is closer to a opportunistic
screening scenario with a prevalence of PCa of 28 %,
more common than the 46 % given by the referenced
nomogram. This fact makes it particularly applicable in
daily practice compared to the referenced nomogram
(international, multicentre, multiethnic, different PSA
assays used).
Conclusions
We validate the PCA3-based nomogram in IBx pub-
lished by Hansen et al. reinforcing its higher utility when
PCA3 is used within a nomogram and selecting cases
for its use. We find an overestimation of probabilities
and minimal loss in the discrimination power of the
model, but we can confirm it as a valid tool for our
population. Using a new methodology, we propose 40 %
as the most reliable threshold point to use the proposed
nomogram recommending or not a healthy man an IBx
in front of an opportunistic screening. This threshold
offers us an optimal tool to help a well-informed man in
his decision.
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